B
Baylink Biosciences develops next-generation Antibody Drug Conjugates (ADCs) utilizing breakthrough linker technology to enable innovative payloads. Their novel linkers expand payload diversity, allowing the use of hydrophobic drugs while reducing off-target effects for improved tumor delivery. The company focuses on advancing precision ADCs by addressing challenges in therapeutic index and payload options, including protein degrader ADCs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Baylink Biosciences develops next-generation Antibody Drug Conjugates (ADCs) utilizing breakthrough linker technology to enable innovative payloads. Their novel linkers expand payload diversity, allowing the use of hydrophobic drugs while reducing off-target effects for improved tumor delivery. The company focuses on advancing precision ADCs by addressing challenges in therapeutic index and payload options, including protein degrader ADCs.